14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma Retraction in /10.3892/etm.2024.12368

Liu,Liang; Liu,Zhixiong; Wang,Hao; Chen,Long; Ruan,Fuqiang; Zhang,Jihui; Hu,Yi; Luo,Hengshan; Wen,Shuai

doi:10.3892/etm.2017.5664

14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma

Retraction in: /10.3892/etm.2024.12368

Authors:
- Liang Liu
- Zhixiong Liu
- Hao Wang
- Long Chen
- Fuqiang Ruan
- Jihui Zhang
- Yi Hu
- Hengshan Luo
- Shuai Wen
View Affiliations

Affiliations: Department of Neurosurgery, People's Hospital of Ningxiang County, Ningxiang, Hunan 410600, P.R. China, Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, Hunan 410078, P.R. China
Published online on: December 21, 2017 https://doi.org/10.3892/etm.2017.5664
Pages: 2381-2387
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is a type of tumor that affects the central nervous system. It has been demonstrated that 14‑3‑3β, a protein that is mainly concentrated in the brain, serves an important role in tumor regulation. However, the mechanism of action of 14‑3‑3β that underlies the pathogenesis of glioma remains to be elucidated. In the present study, 14‑3‑3β was silenced by RNA interference in the human glioma cell line U373‑MG. Following knockdown of 14‑3‑3β, the proliferation, colony formation, cell cycle progression, migration and invasion of U373‑MG cells were significantly decreased (P<0.01), whereas cell apoptosis was increased (P<0.01). Furthermore, in a tumor xenograft experiment, silencing 14‑3‑3β significantly inhibited the in vivo tumor growth of U373‑MG cells (P<0.01). The results demonstrated that 14‑3‑3β levels were significantly higher in human glioma tissues compared with normal brain tissues (P<0.01) and high 14‑3‑3β expression was significantly associated with advanced pathological grade (P<0.03) and low Karnofsky performance scale (P<0.003). Patients with glioma who had high 14‑3‑3β levels had a significantly shorter survival time compared with those with low expression of 14‑3‑3β (P=0.031), suggesting that 14‑3‑3β may be an effective predictor of the prognosis of patients with glioma. The results of the present study indicate that 14‑3‑3β serves an oncogenic role in glioma, suggesting that 14‑3‑3β may have potential as a promising therapeutic target for glioma.

View Figures

View References

1	Louis DN: Molecular pathology of malignant gliomas. Annu Rev Pathol. 1:97–117. 2006. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol. 16:162–172. 2006. View Article : Google Scholar : PubMed/NCBI
5	Tzivion G, Gupta VS, Kaplun L and Balan V: 14-3-3 proteins as potential oncogenes. Semin Cancer Biol. 16:203–213. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hermeking H: The 14-3-3 cancer connection. Nat Rev Cancer. 3:931–943. 2003. View Article : Google Scholar : PubMed/NCBI
7	Qi W, Liu X, Qiao D and Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer. 113:359–363. 2005. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, Khuri FR and Fu H: Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA. 105:pp. 162–167. 2008; View Article : Google Scholar : PubMed/NCBI
9	Li DJ, Deng G, Xiao ZQ, Yao HX, Li C, Peng F, Li MY, Zhang PF, Chen YH and Chen ZC: Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett. 279:65–73. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, et al: Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem. 106:858–866. 2009. View Article : Google Scholar : PubMed/NCBI
11	Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin Cancer Res. 10:2687–2693. 2004. View Article : Google Scholar : PubMed/NCBI
12	Yang X, Cao W, Lin H, Zhang W, Lin W, Cao L, Zhen H, Huo J and Zhang X: Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci. 276:54–59. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sugiyama A, Miyagi Y, Komiya Y, Kurabe N, Kitanaka C, Kato N, Nagashima Y, Kuchino Y and Tashiro F: Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis. 24:1549–1559. 2003. View Article : Google Scholar : PubMed/NCBI
14	Takihara Y, Matsuda Y and Hara J: Role of the beta isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation. Carcinogenesis. 21:2073–2077. 2000. View Article : Google Scholar : PubMed/NCBI
15	Musholt TJ, Brehm C, Hanack J, von Wasielewski R and Musholt PB: Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1. J Surg Res. 131:15–25. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zeng Y, Li Y, Chen RS, He X, Yang L and Li W: Overexpression of xCT induces up-regulation of 14-3-3beta in Kaposi's sarcoma. Biosci Rep. 30:277–283. 2010. View Article : Google Scholar : PubMed/NCBI
17	Baxter HC, Fraser JR, Liu WG, Forster JL, Clokie S, Steinacker P, Otto M, Bahn E, Wiltfang J and Aitken A: Specific 14-3-3 isoform detection and immunolocalization in prion diseases. Biochem Soc Trans. 30:387–391. 2002. View Article : Google Scholar : PubMed/NCBI
18	Boston PF, Jackson P, Kynoch PA and Thompson RJ: Purification, properties, and immunohistochemical localisation of human brain 14-3-3 protein. J Neurochem. 38:1466–1474. 1982. View Article : Google Scholar : PubMed/NCBI
19	Yan Y, Xu Y, Gao YY, Zong ZH, Zhang Q, Li C and Wang HQ: Implication of 14-3-3ε and 14-3-3θ/τ in proteasome inhibition-induced apoptosis of glioma cells. Cancer Sci. 104:55–61. 2013. View Article : Google Scholar : PubMed/NCBI
20	Cao W, Yang X, Zhou J, Teng Z, Cao L, Zhang X and Fei Z: Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis. 15:230–241. 2010. View Article : Google Scholar : PubMed/NCBI
21	Park SG, Jung S, Ryu HH, Jung TY, Moon KS, Kim IY, Jeong YI, Pei J, Park SJ and Kang SS: Role of 14-3-3-beta in the migration and invasion in human malignant glioma cell line U87MG. Neurol Res. 34:893–900. 2012. View Article : Google Scholar : PubMed/NCBI
22	Timerman D and Yeung CM: Identity confusion of glioma cell lines. Gene. 536:221–222. 2014. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
25	Baldin V: 14-3-3 proteins and growth control. Prog Cell Cycle Res. 4:49–60. 2000. View Article : Google Scholar : PubMed/NCBI
26	Tzivion G, Shen YH and Zhu J: 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene. 20:6331–6338. 2001. View Article : Google Scholar : PubMed/NCBI
27	Wilker E and Yaffe MB: 14-3-3 Proteins-a focus on cancer and human disease. J Mol Cell Cardiol. 37:633–642. 2004. View Article : Google Scholar : PubMed/NCBI
28	Zang D, Li X and Zhang L: 14-3-3zeta Overexpression and abnormal β-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin Exp Med. 10:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
29	Luo J, Feng J, Lu J, Wang Y, Tang X, Xie F and Li W: Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis. Med Oncol. 27:791–797. 2010. View Article : Google Scholar : PubMed/NCBI
30	Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T and Shibui S: Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 29:192–200. 2012. View Article : Google Scholar : PubMed/NCBI
31	Fu H, Subramanian RR and Masters SC: 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol. 40:617–647. 2000. View Article : Google Scholar : PubMed/NCBI
32	Mhawech P: 14-3-3 proteins-an update. Cell Res. 15:228–236. 2005. View Article : Google Scholar : PubMed/NCBI
33	Gong F, Wang G, Ye J, Li T, Bai H and Wang W: 14-3-3β regulates the proliferation of glioma cells through the GSK3β/β-catenin signaling pathway. Oncol Rep. 30:2976–2982. 2013. View Article : Google Scholar : PubMed/NCBI